

See editorial comment on page 147

Dialysis dose measurements of Kt by ionic dialysance reveals less dialysis adequacy than the Kt/V_{UREA} -based method in critically ill patients with acute renal failure

N. Serra Cabañas, X. Barros Freiría, J. Garro Martínez, M. Blasco Pelicano, F. Maduell Canals, A. Torras Rabasa, E. Poch López de Briñas

Nephrology and Renal Transplant Department. Hospital Clínic. IDIBAPS. Universidad de Barcelona. Spain.

Nefrología 2010;30(2):232-5

ABSTRACT

Introduction: Measurement of dialysis dose by methods based on urea kinetics (Kt/V_{UREA}) are hardly applicable to critical ill patients with acute renal failure (ARF). However, it is the base of the ADQI consensus recommendation for the target minimum dose. **Objective:** To evaluate the usefulness of the real-time measurement of delivered dialysis dose (Kt) by means of the ionic dialysance (Kt_{DI}) in the critically ill patient and to compare adequacy of dialysis dose between Kt_{DI} and traditional Kt/V_{UREA} . **Material and methods:** Prospective observational study in 17 critically ill patients with ARF requiring acute hemodialysis with a predefined prescription for the study (51 measures). **Results:** The mean delivered Kt/V_{UREA} was 1.19 ± 0.14 , with 59% of the sessions with values equal or above the ADQI recommendation. On the contrary, the mean Kt_{DI} values obtained was 37.6 ± 1 l, with only 29.4% of the sessions being equal or greater than the recommended values. **Conclusions:** Dialysis dose monitoring by means of Kt_{DI} reveals a lower degree of adequacy as compared to the traditional Kt/V_{UREA} method. The dynamic character of Kt_{DI} monitoring can allow the adaptation of each dialysis session («K» and/or «t») in order to achieve the recommended dose.

Key words: Dialysis dose. Haemodialysis. Ionic dialysance. Acute renal failure.

La medida de la dosis de diálisis mediante Kt por dialisancia iónica revela una menor adecuación que la medida por Kt/V_{UREA} en el fracaso renal agudo de pacientes críticos

RESUMEN

Introducción: La medida de la dosis de hemodiálisis basada en la cinética de la urea (Kt/V_{UREA}) adolece de problemas de aplicabilidad en el paciente crítico con insuficiencia renal aguda (IRA). No obstante, las recomendaciones de consenso sobre la dosis se basan en el Kt/V_{UREA} . **Objetivo:** Evaluar la utilidad de la medida en tiempo real de la dosis de diálisis suministrada (Kt) mediante dialisancia iónica (Kt_{DI}) en el paciente crítico y el grado de adecuación de la dosis en comparación con la medida estándar del Kt/V_{UREA} . **Material y métodos:** Estudio prospectivo observacional de medida de dosis en 17 pacientes críticos con IRA sometidos a 3 sesiones de diálisis intermitente con prescripción predefinida para este estudio (en total 51 medidas). **Resultados:** El Kt/V_{UREA} medio suministrado por sesión fue de $1,19 \pm 0,14$, con un 59% de sesiones consideradas adecuadas por lo recomendado por la ADQI. Por el contrario, la media de Kt_{DI} obtenida fue de $37,6 \pm 1$ l, con sólo un 29,4% igual o por encima del valor mínimo recomendado. **Conclusiones:** La monitorización de la dosis mediante Kt_{DI} revela un menor grado de adecuación en comparación con el Kt/V_{UREA} . El carácter dinámico de la medida de Kt_{DI} puede permitir la adaptación de cada sesión de diálisis («K» y/o «t») con el fin de lograr el objetivo de dosis mínima.

Palabras clave: Dosis de diálisis. Dialisancia iónica. Hemodiálisis. Insuficiencia renal aguda.

INTRODUCTION

Acute renal failure (ARF) is a frequent complication in critical patients (with an incidence rate of between 5 and

Correspondence: Esteban Poch López de Briñas
Servicio de Nefrología y Trasplante Renal.
Hospital Clínic. IDIBAPS. Universidad de Barcelona. Barcelona. Spain.
epoch@clinic.ub.es

This study was presented in the 39th National Congress of the Spanish Society of Nephrology, held in Pamplona from 3-6 October 2009, and published in summary form: Serra N, Barros X, Garro J, Blasco M, Maduell F, Torras A, Poch E. Using ionic dialysance to measure haemodialysis dose in critical patients with acute renal failure. Nefrología 2009;29(Suppl. 2):62. .

25%), and it increases mortality significantly, particularly in cases that require renal replacement therapy, for which mortality can reach rates between 50 and 70%.¹

There is no agreement whether the intermittent haemodialysis (IHD) dose for ARF in the critical patient is positively linked to survival. A study published in 2002 indicated that daily dialysis improved survival and accelerated renal recovery,² although this idea was refuted in a very large study published recently.³ One of the criticisms of the first study was that mean Kt/V_{UREA} supplied per session was only 0.94, compared with 1.3 in the second study. From these studies and others, we deduce that there is a minimum effective dose that should be reached, and that a regimen based on IHD lasting four to five hours on alternate days has a similar mortality to regimens with a higher frequency, provided that the dose administered per session is appropriate.

The problem with calculating the dialysis dose in a critical patient is that no method has been validated to date. V_{UREA} is difficult to estimate in acute patients, and therefore Kt/V_{UREA} , which has been thoroughly validated for calculating IHD doses in ARF patients, should not be used for patients in critical condition.

Although this is well-known, the ADQI (Acute Dialysis Quality Initiative) recommendations are based on the Kt/V_{UREA} method, which is used in most important studies.^{2,3} In recent years, one method for measuring IHD dose, ionic dialysance (ID) has been validated for CRF.⁵ The study is based on continuous monitoring of the dialysate conductivity which some haemodialysis monitors measure automatically. Recently, one study used this method in critical patients with ARF and compared it with the gold standard method of fractional dialysate sampling, which showed excellent correlation (0.96) between Kt_{ID} and $Kt_{\text{dialysate}}$.⁶

The main objective of the present study was to evaluate application of the Kt_{ID} measurement in normal clinical practice and compare it with the Kt/V_{UREA} method, thus evaluating the prevalence of adequate dialysis in critical patients with ARF.

MATERIAL AND METHODS

This prospective observational study was carried out in Hospital Clínic of Barcelona between September 2007 and June 2009. It includes all critical patients with ARF on renal replacement therapy with intermittent haemodialysis in a standard regimen of sessions lasting at least three hours every 48 hours who were treated by our service during that period. Vascular access consisted of a percutaneous 11.5 F catheter that was either femoral (24cm long) or jugular (15 or 20cm long depending on whether it was on the right or

left, respectively). The dialysis characteristics were identical in all patients and similar to the treatment systematically applied in our centre: Fresenius 4008S monitor, frequency of every 48 hours, duration four hours, FX 60 membrane (Fresenius, surface area 1.4m²), blood flow of 250ml/min, dialysate flow 500ml/min, conductivity value of 14.5mS/cm and dialysate temperature of 35-36° C. In all dialysis sessions, Kt was determined using ID (Kt_{ID}) and during the first three IHD sessions indicated in each patient, we determined Kt/V_{UREA} by the Daugirdas⁷ method. In addition, we registered several variables that may affect the administered dialysis dose, such as the need for vasoactive drugs, mechanical ventilation, septic shock, catheter dysfunction requiring reversal of the arterial and venous lines, and episodes of hypotension during the session defined as a drop of 20mmHg in systolic pressure after beginning the dialysis or a need to increase the dose of vasoactive drugs.

Statistical analysis

Statistical analysis was performed using SPSS software, version 15.0 (Chicago, USA). Values are expressed as a mean \pm standard error of the mean (SEM). Comparison of means was performed using Student's t-test or non-parametric tests for variables without a normal distribution. Qualitative variables were compared using Chi-squared test. Statistical significance was established for p-values < 0.05.

RESULTS

The study included 17 critical patients with ARF (six men and eleven women) with a mean age of 61.7 ± 3.7 years. Five of them were admitted to the ICU due to septic shock. Six patients were treated with invasive mechanical ventilation, and three required treatment with vasoactive drugs (noradrenaline or dopamine) in low doses (table 1). The characteristics of the dialysis sessions corresponded with the guidelines for the present study (table 1).

The mean Kt/V_{UREA} per session was 1.19 ± 0.14 ; 59% of the sessions had a value higher than that recommended by ADQI (1.2 or higher, regardless of sex), with 50% of men and 63.3% of women receiving the minimum required dose (figure 1).

Meanwhile, the mean Kt_{ID} was $37.6 \pm 1\text{L}$, and the minimum recommended Kt_{ID} was reached in only 29.48 of the sessions (40L for women and 45L for men). Mean Kt_{ID} values were $37.5 \pm 1.5\text{L}$ for men and $37.6 \pm 1.3\text{L}$ in women. If we consider the Kt_{ID} values recommended for patients with chronic renal failure (CRF) according to Lowrie et al⁸ (Kt_{ID} between 45 and 50L for men and Kt_{ID} between 40 and 45L for women), recommendations were only met in 42.4% of all sessions for women and 5.6% of sessions for men (figure 1).

Table 1. Clinical characteristics of the included patients and haemodialysis sessions.

Clinical characteristics	
Age	61.7 ± 3.7
Sex (M/F)	6/11
Prior CRF (%)	4 (23.5)
Septic shock (%)	5 (29.4)
Invasive mechanical ventilation (%)	6 (35.3)
Vasoactive drugs (%)	3 (17.6)
Dialysis characteristics	
Blood flow (ml/min)	252 ± 37
Dialysate flow (ml/min)	506 ± 43
Duration (minutes)	240 ± 6.1

There were no significant differences in the mean Kt/V_{UREA} or mean Kt_{ID} among patients grouped according to sex, need for vasoactive drugs, presence of septic shock, prior history of CRF, need for mechanical ventilation or hypotension episodes (data not shown). In sessions in which catheter dysfunction led to line reversal, values of Kt/V_{UREA} (0.84 ± 0.27 compared to 1.27 ± 0.16) and Kt_{ID} (32 ± 1 compared to 37 ± 1.8) were numerically lower, but the difference did not reach a statistically significant level ($p = 0.28$ and $p = 0.22$, respectively).

DISCUSSION

In this study, we evaluated the dialysis dose administered to a group of ARF patients in critical condition and compared the dialysis adequacy between direct measurement using Kt_{ID} and Kt/V_{UREA} , the classical method which is still being recommended. We observed that use of Kt_{ID} can identify the patient subgroup which appears to receive an adequate dose of dialysis according to the Kt/V_{UREA} measurement, but which could be considered as underdialysed. This observation concurs with that of a recent study of CRF patients in which the Kt_{ID} value identified between 30 and 40% of the patients as underdialysed, although they met the minimum dosage of 1.3 recommended for CRF according to the Kt/V_{UREA} measurement.⁹ Furthermore, among the ARF patients we see a low percentages of compliance with one method or another, which points to the need to focus our efforts on using a reliable, easy method for calculating the proper dose in these patients whose mortality rate is high.

Although there have recently been doubts about the correlation between dialysis doses and survival in ARF,^{2,3} it is true that there is a minimum dialysis dose in this patient group, established as a Kt/V_{UREA} level of 1.2 which is partly based on recommendations for CRF patients.^{4,10} However, specific studies in ARF patients will be necessary in order to

determine the minimum effective dose. In any case, we know that this measurement is not transferrable to this type of patients who are not in a state of metabolic equilibrium and have an elevated protein catabolism, changing volaemic states, possible residual renal function, and in whom the estimated urea distribution volume (V_{UREA}) is uncertain. Therefore, while V_{UREA} may be inferred from total body water volume in healthy individuals or those with CRF, it has been observed between 7 and 50% higher in acute patients.¹¹ Underdialysis is common in ARF. Moreover, a study in ARF patients showed that 70% of the treatments provided a Kt/V_{UREA} value below 1.2, and that patient weight, sex and blood flow affected the resulting dose.¹²

Various factors are involved in each haemodialysis session, and they may affect dialysis effectiveness. It therefore seems logical that control systems were created to measure the dose the patient receives each session, in real time. At present, different monitors include biosensors that use the machine’s own conductivity probes to provide non-invasive measurements of the effective ionic dialysance, equivalent to urea clearance (K). This enables us to calculate the dialysis dose without a work overload or analytical measurements, and at no additional cost.¹³⁻¹⁵

Using Kt has its advantages. Both K and t are real measurements from the monitor, cannot be manipulated by the user and may be used in all dialysis sessions. Initial recommendations in 1999 were based on a minimum Kt of 40 to 45L for women and 45 to 50L for men with CRF⁸. These indications were subsequently validated,¹⁶ and it was observed that patient group receiving between 4 and 7 litres




Figure 1. Percentages of haemodialysis sessions that met the proposed minimum criteria ($Kt/V_{UREA} \geq 40_{-1.2}$ for women; $Kt_{ID} \geq 45$ for men).

less than the prescribed amount experienced a 10% increase in mortality; the group receiving between 7 and 11 litres less experienced a 25% increase; and the group with 11 or more litres less than the prescribed amount experienced a 30% increase. SEN (Spanish Association of Nephrology) guidelines recommend a minimum of 45L of Kt for CRF patients who have ionic dialysance monitors.^{17,18}

There is no minimum recommended dose of Kt_{ID} in ARF, and no data about its effect on mortality, which is why we have taken the recommendations for CRF in the lowest value in the range. The main advantage of measuring Kt_{ID} automatically is that it permits us to adapt the conditions of each dialysis session in order to reach the optimal dose. On this topic, a recent study showed that in patients equipped with catheters in the haemodialysis programme, it was necessary to prolong the dialysis session by 30 minutes in order to reach target Kt, compared with patients with an arteriovenous fistula (IAVF).¹⁹ Although systematically prolonging dialysis sessions (to five hours, for example) in all acute patients is not an uncommon practice, it is true that this measurement is not always necessary³ and, in this sense, continuous Kt_{ID} monitoring may help in adapting session length in order to reach the minimum recommended dose.

In conclusion, measuring the dialysis dose using the Kt_{ID} method identifies a higher number of inadequate sessions than the standard Kt/V_{UREA} method does, and the former therefore appears to be a useful method for delivering a minimum dialysis dose in ARF patients.

Acknowledgements

The authors would like to thank the Grupo de Trabajo del Enfermo Crítico (Critically Ill Patients Study Group) at Hospital Clínic of Barcelona for its contributions to the completion of this study. The study was funded in part by FIS PI0800140 and ISCIII-Retic-RD06, REDinREN (16/06).

REFERENCES

- Lameire N, Van BW, Vanholder R. Acute renal failure. *Lancet* 2005;65(9457):417-30.
- Schiffli H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. *N Engl J Med* 2002;346(5):305-10.
- Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 2008;359(1):7-20.
- Ricci Z, Bellomo R, Ronco C. Dose of dialysis in acute renal failure. *Clin J Am Soc Nephrol* 2006;1(3):380-8.
- Lindsay RM, Bene B, Goux N, Heidenheim AP, Landgren C, Sternby J. Relationship between effective ionic dialysance and in vivo urea clearance during hemodialysis. *Am J Kidney Dis* 2001;38(3):565-74.
- Ridel C, Osman D, Mercadal L, et al. Ionic dialysance: a new valid parameter for quantification of dialysis efficiency in acute renal failure? *Intens Care Med* 2007;33(3):460-5.
- Daugirdas JT, Schneditz D. Overestimation of hemodialysis dose depends on dialysis efficiency by regional blood flow but not by conventional two pool urea kinetic analysis. *ASAIO J* 1995;41(3):M719-24.
- Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF. The urea [clearance • dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. *Kidney Int* 1999;56(2):729-37.
- Maduell F, Vera M, Serra N et al. Kt as control and follow-up of the dose at a hemodialysis unit. *Nefrologia* 2008;28(1):43-7.
- Di Giulio S, Meschini L, Triolo G. Dialysis outcome quality initiative (DOQI) guideline for hemodialysis adequacy. *Int J Artif Organs* 1998;21(11):757-61.
- Himmelfarb J, Evanson J, Hakim RM, Freedman S, Shyr Y, Ikizler TA. Urea volume of distribution exceeds total body water in patients with acute renal failure. *Kidney Int* 2002;61(1):317-23.
- Evanson JA, Himmelfarb J, Wingard R, et al. Prescribed versus delivered dialysis in acute renal failure patients. *Am J Kidney Dis* 1998;32(5):731-8.
- Petitclerc T, Goux N, Reynier AL, Bene B. A model for non-invasive estimation of in vivo dialyzer performances and patient's conductivity during hemodialysis. *Int J Artif Organs* 1993;16(8):585-91.
- Petitclerc T, Bene B, Jacobs C, Jaudon MC, Goux N. Non-invasive monitoring of effective dialysis dose delivered to the haemodialysis patient. *Nephrol Dial Transplant* 1995;10(2):212-6.
- Steil H, Kaufman AM, Morris AT, Levin NW, Polaschegg HD. In vivo verification of an automatic noninvasive system for real time Kt evaluation. *ASAIO J* 1993;39(3):M348-52.
- Lowrie EG, Li Z, Ofsthun N, Lazarus JM. The online measurement of hemodialysis dose (Kt): clinical outcome as a function of body surface area. *Kidney Int* 2005;68(3):1344-54.
- Maduell F, García M, Alcázar R. Dosage and adaptation of dialytic treatment. *Hemodialysis centers guides*. *Nefrologia* 2006;26(Suppl 8):15-21.
- Guías S.E.N. Actuación en el Fracaso Renal Agudo: *Nefrologia* 2007;27(Suppl 3):1-274.
- Maduell F, Vera M, Arias M, et al. How much should dialysis time be increased when catheters are used? *Nefrologia* 2008;28(6):633-6.